The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CMMB | -81.69% | -99.15% | -61.44% | -99% |
| S&P | +13.95% | +78.35% | +12.25% | +74% |
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.
No news articles found for Chemomab Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $13.61M | -54.0% |
| Market Cap / Employee | $850.34K | 0.0% |
| Employees | 16 | 0.0% |
| Net Income | -$1,750.15K | 49.9% |
| EBITDA | -$3,468.88K | 15.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.12M | 6.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $0.00K | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -60.98% | 4.4% |
| Return On Invested Capital | -132.58% | 14.4% |
No data available for this period.
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.52 | 1.98 | 2.47 | 1.40 | -22.68% |
| Price to Tangible Book Value | 8.37 | 5.04 | 8.42 | 1.40 | -84.47% |
| Enterprise Value to EBITDA | -4.91 | -3.88 | -4.67 | -1.74 | - |
| Return on Equity | -91.8% | -113.0% | -120.8% | -73.6% | -12.61% |
| Total Debt | $324.00K | $292.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
